Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its first quarter 2025 financial results announcement for May 13, 2025. The company will host a conference call and webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register for the conference call at least one day in advance. The webcast will be accessible through the company's website and will remain available for a minimum of 30 days in the Investors section.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented extended results from its plasma pTau217 assay screening strategy for the Phase 2 ALTITUDE-AD clinical trial of sabirnetug at the AD/PD 2025 conference in Vienna and AAN Annual Meeting in San Diego. The pTau217 enrichment strategy successfully reduced the need for amyloid PET scans and CSF testing during participant screening.
The company showcased multiple research developments, including: a method to produce stable Aβ monomers for selectivity assays, an iPSC-derived neuronal model demonstrating sabirnetug's ability to block AβO binding to synapses, and a comparative study of anti-amyloid beta antibodies' binding profiles. Additionally, biomarker results from the Phase 1 INTERCEPT-AD trial were recently published, with ongoing evaluation of synaptic biomarkers VAMP2 and neurogranin in CSF.
Acumen Pharmaceuticals (NASDAQ: ABOS) has reported its financial results for 2024 and provided key business updates. The company completed enrollment in its Phase 2 ALTITUDE-AD study, investigating sabirnetug for early Alzheimer's disease, with topline results expected in late 2026.
Key financial highlights include cash position of $231.5 million as of December 31, 2024, expected to fund operations into first half of 2027. The company reported increased R&D expenses of $93.8 million (vs $42.3 million in 2023) and G&A expenses of $20.2 million (vs $18.8 million in 2023). Net loss widened to $102.3 million from $52.4 million in 2023.
Recent developments include positive Phase 1 results for a subcutaneous sabirnetug formulation and the publication of INTERCEPT-AD study results showing the drug was well-tolerated with dose-dependent target engagement.
Acumen Pharmaceuticals (NASDAQ: ABOS) has completed enrollment ahead of schedule for its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer's disease patients. The trial enrolled 542 patients across the US, Canada, EU, and UK.
The study will evaluate two dose levels (35mg/kg and 50mg/kg) administered every four weeks versus placebo. Topline results, including efficacy and safety data, are expected in late 2026. The primary endpoint is measuring change in the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months.
Sabirnetug is the first humanized monoclonal antibody showing selective target engagement of amyloid beta oligomers (AβOs) in AD patients. The Phase 1 INTERCEPT-AD trial demonstrated the drug was generally well-tolerated with low ARIA-E rates, dose-dependent target engagement, and significant amyloid plaque reduction versus placebo at higher doses.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel treatment for Alzheimer's disease targeting toxic soluble amyloid beta oligomers, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025.
The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in numbers and PIN. The webcast will remain accessible for a minimum of 30 days through the Investors section of Acumen's website.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced positive topline results from its Phase 1 study comparing subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy volunteers. The study demonstrated that weekly SC administration of sabirnetug was well-tolerated, with sufficient systemic exposure to support further clinical development.
The trial included 12 subjects receiving single IV doses of 2,800 mg and 16 subjects receiving four weekly SC doses of 1,200 mg. The most common adverse events were mild injection site reactions (62.5%), which all resolved. The SC formulation utilizes Halozyme's ENHANZE® drug delivery technology, enabling large volume SC injection with improved dispersion and absorption.
Sabirnetug, the first humanized monoclonal antibody showing selective target engagement of amyloid beta oligomers (AβOs) in Alzheimer's disease patients, is being developed as a more convenient administration option compared to IV treatment. The Phase 2 ALTITUDE-AD study of IV sabirnetug is currently ongoing.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced upcoming scientific presentations at two major conferences: the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Vienna from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025.
The presentations will highlight the implementation of a validated research-use plasma pTau217 assay in screening participants for the Phase 2 ALTITUDE-AD study of sabirnetug, their novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for early symptomatic Alzheimer's disease treatment.
Key presentations include:
- Oral presentation on ALTITUDE-AD study at AD/PD on April 1
- Two poster presentations at AD/PD focusing on amyloid beta preparation and neuronal binding studies
- Oral presentation on plasma pTau217 screening at AAN on April 7
- Poster presentation on INTERCEPT-AD biomarker results at AAN on April 9
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences.
The company will engage in webcast fireside chats at:
- UBS Virtual CNS Day on March 17, 2025, at 12:30 p.m. ET
- Stifel Virtual CNS Days on March 18, 2025, at 3:30 p.m. ET
The webcasts will be accessible through the Investors section of Acumen's website (www.acumenpharm.com) and will remain available for 90 days after the events.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced the publication of Phase 1 INTERCEPT-AD clinical trial results for sabirnetug (ACU193) in the Journal of Prevention of Alzheimer's Disease. The study, involving 65 early Alzheimer's disease patients, demonstrated that sabirnetug was generally well-tolerated with dose-dependent target engagement of amyloid beta oligomers (AβOs) and significant amyloid plaque reduction in higher dose cohorts.
Key findings include selective AβO target engagement, low overall levels of ARIA-E, and only one participant experiencing mild ARIA-E that resolved within four weeks. The company is currently conducting the Phase 2 ALTITUDE-AD trial, which began in May 2024 and aims to enroll approximately 540 adults across 75 sites in the U.S., Canada, EU, and U.K. Enrollment completion is expected in the first half of 2025.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 3:00 p.m. ET. Interested parties can access the live webcast through the Investors section of www.acumenpharm.com, where it will remain available for 90 days. The company specializes in developing novel therapeutics targeting toxic soluble amyloid beta oligomers.